New hope for hemophilia b: Long-Lasting clotting factor under study

NCT ID NCT06399289

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 21 times

Summary

This study tests a new drug called rIX-FP, which is a long-lasting clotting factor, in 23 Chinese men with hemophilia B. The goal is to see how well it prevents and treats bleeding episodes when given regularly. Participants receive the drug as a routine shot to keep their clotting levels stable and can also get extra doses if they have a bleed or need surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, 550004, China

  • Beijing Children's Hospital

    Beijing, Beijing Municipality, 100045, China

  • Hospital of Hematology, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, 300020, China

  • Jinan Central Hospital

    Jinan, Shandong, 250013, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, 510515, China

  • North China University Of Science And Technology Affiliated Hospital

    Tangshan, Hebei, 63000, China

  • Union Hospital Affiliated to Fujian Medical University

    Fuzhou, Fujian, 350001, China

Conditions

Explore the condition pages connected to this study.